Biogen cuts profit forecast on Alzheimer's drug launch, deal costs
Reuters
Published Nov 08, 2023 07:45AM ET
Updated Nov 08, 2023 12:41PM ET
By Bhanvi Satija and Mariam Sunny
(Reuters) -Biogen on Wednesday cut its annual profit forecast to below Wall Street estimates due to higher costs associated with the launch of Alzheimer's drug Leqembi and its $6.5 billion Reata Pharmaceuticals (NASDAQ:RETA) acquisition, and shares fell more than 4%.
About 800 people were currently being treated with Leqembi, Biogen (NASDAQ:BIIB)'s Alzheimer's partner, Japanese drugmaker Eisai, said on Tuesday, making Biogen's target of 10,000 patients on the drug by the end of March 2024 look increasingly difficult.
"I think people were looking for a few more patients on therapy there," said William Blair analyst Myles Minter, adding that it was a "long way" from hitting that 10,000-patient goal.
Biogen said it now expects full-year adjusted profit of $14.50 to $15.00 per share, the new high end of the range matching the low end of its previous forecast of $15 to $16. Analysts were estimating $15.26 per share.
Biogen shares have declined over 11% so far this year as its older multiple sclerosis drugs, long a growth driver for the company, face intense competition from cheaper versions and other rival treatments.
Biogen urged investors to focus on its newer treatments including postpartum depression drug Zurzuvae, and Friedreich ataxia treatment Skyclarys, acquired with the purchase of rare disease drugmaker Reata.
"This really is the start of a transition from a historical maturing product portfolio of multiple sclerosis to a new portfolio," CEO Christopher Viehbacher said on a call with reporters.
"We now have the elements to grow sustainably so our focus is no longer on doing anything of significance in M&A at least for the time being," Viehbacher said.
Since taking the helm a year ago, the former Sanofi (NASDAQ:SNY) CEO has led efforts to cut expenses and help Biogen recover from missteps around the Alzheimer's drug Aduhelm, which never gained traction after a controversial approval.
"Whether the 'new Biogen' has arrived remains to be seen," said BMO Capital Markets analyst Evan Seigerman.
Eisai on Tuesday said it was targeting revenue of 10 billion yen ($66.5 million) from Leqembi by March. Leqembi revenue recorded by Eisai was about $2 million for the third quarter.
Biogen said it expects annual sales to decline in low-single digits from last year, up from a previous forecast of a mid-single digit drop.
Get The News You Want
Total expenses more than doubled to $2.67 billion in the third quarter.
Third-quarter profit of $4.36 per share topped Wall Street estimates by 39 cents, buoyed by sales of Spinraza, its expensive treatment for spinal muscular atrophy, and higher contract manufacturing revenue.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.